Brief: Poxel Announces Positive Results From Phase 2a NASH Trial With PXL770

Poxel SA

01/10/2020 07:05

Oct 1 (Reuters) - POXEL SA  POXEL.PA :
    * POXEL ANNOUNCES POSITIVE RESULTS FROM PHASE 2A NASH TRIAL
WITH
PXL770, AN ORAL FIRST-IN-CLASS DIRECT AMPK ACTIVATOR
    * PHASE 2A TRIAL FOR TREATMENT OF NASH MET ITS PRIMARY
EFFICACY
ENDPOINT
    * PXL770-TREATED PATIENTS ACHIEVED STATISTICALLY SIGNIFICANT
IMPROVEMENT IN RELATIVE DECREASE IN LIVER FAT MASS MEASURED BY
MAGNETIC RESONANCE IMAGING-ESTIMATED PROTON DENSITY FAT FRACTION
    * KEY SECONDARY MEASURES IN PXL770-TREATED PATIENTS INCLUDED
STATISTICALLY SIGNIFICANT OBSERVED IMPROVEMENTS IN LIVER ENZYMES
    * PXL770 WAS OBSERVED TO BE SAFE AND WELL TOLERATED; PROFILE
SUPPORTS FURTHER EVALUATION FOR COMBINATION USE
    * FIRST HUMAN CLINICAL ASSESSMENT OF A DIRECT AMPK
ACTIVATOR;
RESULTS SUPPORT POTENTIAL FOR DEVELOPMENT IN NASH INCLUDING KEY
HIGH-RISK SUBGROUPS

Source text for Eikon:  ID:nBw5LDD3Xa 
Further company coverage:  POXEL.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))